Salaries and welfare increased by $1,025,391, or 15.16%, to $7,790,908 for the three months ended June 30, 2026 from $6,765,517 for the same period in 2025, mainly due to the inclusion of personnel costs attributable to Waqoo and Cell Pro, which were consolidated beginning in the current-year period, and higher social insurance premiums driven by an increase in headcount at a Japanese subsidiary.

filing / Aug 13, 2026 / receipt

Salaries and welfare increased by $781,400, or 5.92%, to $13,988,659 for the six months ended June 30, 2026 from $13,207,259 for the same period in 2025, mainly due to the inclusion of personnel costs attributable to Waqoo and Cell Pro, which were consolidated beginning in the current-year period, and higher social insurance premiums driven by an increase in headcount at a Japanese subsidiary.

filing / Aug 13, 2026 / receipt

The Company expects to deploy capital for investment opportunities that align with its growth strategy, selectively pursuing prospects in the expanding global medical aesthetics market.

filing / Aug 13, 2026 / receipt

since September 29, 2023, and was appointed as our Chief Financial Officer effective April 1, 2025. Mr. Yoshida has also served as the Executive Vice President and the Chief Financial Officer of SBC Medical Group Co., Ltd.

filing / May 28, 2026 / receipt